59807-53-3

Basic information

• Product Name: 2-ADAMANTANYLETHYLAMINE
• Synonyms: 2-ADAMANTANYLETHYLAMINE;AKOS BC-1153;2-(2-Aminoethyl)adamantane;2-(Adamantan-2-yl)ethanamine;Tricyclo[3.3.1.1(3,7)]decane-2-ethanamine
• CAS NO: 59807-53-3
• Molecular Formula: C₁₂H₂₁N
• Molecular Weight: 179.3
• Product Categories: Adamantane derivatives
• Mol File: 59807-53-3.mol

Chemical Properties

• Boiling Point: 248.5±8.0℃ (760 Torr)
• Flash Point: 99.7±13.3℃
• Appearance: /
• Density: 0.992±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 0.0242mmHg at 25°C
• Refractive Index: 1.521
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-ADAMANTANYLETHYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-ADAMANTANYLETHYLAMINE(59807-53-3)
• EPA Substance Registry System: 2-ADAMANTANYLETHYLAMINE(59807-53-3)

Safety Data

• Hazardous Substances Data: 59807-53-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
2-Adamantanylethylamine is used as a research compound for its potential stimulant effects and its interaction with dopamine and serotonin receptors in the brain. It is being studied for its potential use in the treatment of [application reason] depression, attention deficit hyperactivity disorder (ADHD), and neurodegenerative diseases.
Used in Neurological Treatments:
In the field of neurology, 2-Adamantanylethylamine is used as a potential therapeutic agent for [application reason] managing the symptoms of depression and ADHD, as well as for exploring its effects on neurodegenerative conditions.

InChI:InChI=1/C12H21N/c13-2-1-12-10-4-8-3-9(6-10)7-11(12)5-8/h8-12H,1-7,13H2

Upstream product

• 38121-87-8 adamantan-2-ylacetonitrile 
• 700-58-3 2-Adamantanone 
• 38121-89-0 adamantan-2-ylideneacetonitrile 

Relevant articles and documents

Reduction of unsaturated adamantane-containing nitriles

The regularities of reduction of adamantane-containing unsaturated nitriles with Raney nickel were studied. It was shown that in the reaction conditions simultaneous reduction of both the double bond and the nitrile group occurs. The reduction of 2-(5-hydroxyadamant-2-ylidene)alkyl nitriles requires a longer time.

Multiple Halogenation of Aliphatic C?H Bonds within the Hofmann–L?ffler Manifold

An innovative approach to position-selective polyhalogenation of aliphatic hydrocarbon bonds is presented. The reaction proceeded within the Hofmann-L?ffler manifold with amidyl radicals as the sole mediators to induce selective 1,5- and 1,6-hydrogen-atom transfer followed by halogenation. Multiple halogenation events of up to four innate C?H bond functionalizations were accomplished. The broad applicability of this new entry into polyhalogenation and the resulting synthetic possibilities were demonstrated for a total of 27 different examples including mixed halogenations.

Colloid and nanosized catalysts in organic synthesis: XII. Hydrogenation of carbonitriles catalyzed by nickel nanoparticles

Hydrogenation of carbonitriles catalyzed by nickel nanoparticles in isopropanol proceeds under atmospheric pressure of hydrogen within 6-15 h to yield mainly secondary amines. Hydrogenation of α-aminonitriles results in reductive decyanation. β-Aminonitriles undergo hydrogenolysis at the nitrogen-carbon bond.

Reduction of unsaturated adamantyl-containing nitriles with lithium aluminum hydride in 2-methyltetrahydrofuran

Reduction of unsaturated adamantyl-containing nitriles with lithium aluminum hydride in 2-methyltetrahydrofuran was examined. It was found that under the synthesis conditions a simultaneous reduction of the double bond and the nitrile group successfully o

Condensation of adamantanone with methylene-active compounds

A convenient method was developed for the preparation of potentially bioactive substances with 2-adamantyl radical and of intermediates for their synthesis. Condensation of adamantanone with methylene-active compounds was performed, and the reaction features were determined.

THIAZOLE CARDIOVASCULAR AGENTS

1-Alkylamino-3-(5-carbocyclicalkylaminocarbonylthiazol-2-yloxy)-2-propan ol;5-(5-carbocyclicalkylaminocarbonylthiazol-2-yloxymethylene-N-alkyloxazol idin e and/or 2-substituted oxazolidine derivatives thereof, and methods of making such compounds. The compounds exhibit cardiovascular activity and are useful in the treatment of abnormal heart conditions in mammals. The compounds are also useful in the treatment of hypertension in mammals. The 5-(5-carbocyclicalkylaminocarbonylthiazol-2-yloxymethylene)-N-alkyloxazolid ines and derivatives are also intermediates for the 1-alkylamino-3-(5-carbocyclicalkylaminocarbonylthiazol-2-yloxy)-2-propanols . The 1-alkylamino-3-(5-carbocyclicalkylaminocarbonylthiazol-2-yloxy)-2-propanols can be prepared by base or acid hydrolysis of the corresponding 5-(5-carbocyclicalkylaminocarbonylthiazol-2-yloxymethylene)-N-alkyloxazolid ine or derivative; or by treatment of the corresponding 3-(5-carbocyclicalkylaminocarbonylthiazol-2-yloxy)-2,3-epoxypropane with the desired alkylamine. Similarly the 5-(5-carbocyclicalkylaminocarbonylthiazol-2-yloxymethylene)-N-alkyloxazolid ine or derivative can be prepared from the corresponding 1-alkylamino-3-(5-carbocyclicalkylaminocarbonylthiazol-2-yloxy)-2-propanols via treatment with an aldehyde or ketone.